A carregar...
Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
PURPOSE: The usual first-line strategy of wild-type EGFR (wtEGFR) non-small cell lung cancer (NSCLC) remains cisplatin-based chemotherapy. However, cisplatin often loses effectiveness because most tumors acquire drug resistance over time. As EGFR is the most important pro-survival/proliferation sign...
Na minha lista:
| Publicado no: | J Cancer Res Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7185832/ https://ncbi.nlm.nih.gov/pubmed/32342201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03228-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|